Lataa...
Erelzi<sup>®</sup> – biosimilar of etanercept in the treatment of rheumatic diseases and psoriasis (Resolution of the Expert Panel)
Introduction of biosimilars of biological disease-modifying antirheumatic drugs (bDMARs) into clinical practice has significantly expanded the availability of bDMARD therapy for a wide range of patients with chronic immuno-inflammatory diseases.In 2020, the first biosimilar etanercept Erelzi®, was r...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Russo |
| Julkaistu: |
IMA-PRESS LLC
2021-08-01
|
| Sarja: | Современная ревматология |
| Aiheet: | |
| Linkit: | https://mrj.ima-press.net/mrj/article/view/1183 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|